ZhiCheng Lai

747 total citations · 1 hit paper
26 papers, 503 citations indexed

About

ZhiCheng Lai is a scholar working on Hepatology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, ZhiCheng Lai has authored 26 papers receiving a total of 503 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hepatology, 12 papers in Pathology and Forensic Medicine and 8 papers in Molecular Biology. Recurrent topics in ZhiCheng Lai's work include Hepatocellular Carcinoma Treatment and Prognosis (14 papers), Cancer Mechanisms and Therapy (11 papers) and Liver Disease Diagnosis and Treatment (4 papers). ZhiCheng Lai is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (14 papers), Cancer Mechanisms and Therapy (11 papers) and Liver Disease Diagnosis and Treatment (4 papers). ZhiCheng Lai collaborates with scholars based in China and Hong Kong. ZhiCheng Lai's co-authors include Ming Shi, Minke He, QiJiong Li, Li Xu, Wei Wei, Anna Kan, Yu-Jie Xu, Minshan Chen, Yaojun Zhang and Rong Guo and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Frontiers in Immunology.

In The Last Decade

ZhiCheng Lai

23 papers receiving 501 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial

2022 119 citations ZhiCheng Lai, Minke He et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
ZhiCheng Lai China	11	351	175	140	134	113	26	503
Jong Ryul Eun South Korea	15	304 0.9×	42 0.2×	89 0.6×	106 0.8×	269 2.4×	41	528
MinShan Chen China	7	449 1.3×	233 1.3×	167 1.2×	124 0.9×	134 1.2×	9	592
Hae Lim Lee South Korea	12	359 1.0×	55 0.3×	73 0.5×	115 0.9×	283 2.5×	34	566
Mounes Aliyari Ghasebeh United States	6	141 0.4×	41 0.2×	50 0.4×	72 0.5×	85 0.8×	6	451
Silvia Camera Italy	10	74 0.2×	33 0.2×	75 0.5×	164 1.2×	102 0.9×	27	388
Yvonne Bury United Kingdom	9	111 0.3×	200 1.1×	78 0.6×	61 0.5×	120 1.1×	18	438
Zhao Yin-nong China	10	85 0.2×	55 0.3×	99 0.7×	114 0.9×	77 0.7×	24	406
Giulia Negrini Italy	11	178 0.5×	50 0.3×	125 0.9×	62 0.5×	195 1.7×	13	447
Vennis Lourdusamy United States	5	172 0.5×	38 0.2×	72 0.5×	102 0.8×	97 0.9×	16	320
Miral S. Grandhi United States	8	163 0.5×	55 0.3×	117 0.8×	144 1.1×	110 1.0×	39	544

Countries citing papers authored by ZhiCheng Lai

Since Specialization

Citations

This map shows the geographic impact of ZhiCheng Lai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by ZhiCheng Lai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites ZhiCheng Lai more than expected).

Fields of papers citing papers by ZhiCheng Lai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by ZhiCheng Lai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by ZhiCheng Lai. The network helps show where ZhiCheng Lai may publish in the future.

Co-authorship network of co-authors of ZhiCheng Lai

This figure shows the co-authorship network connecting the top 25 collaborators of ZhiCheng Lai. A scholar is included among the top collaborators of ZhiCheng Lai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with ZhiCheng Lai. ZhiCheng Lai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xu, Yujie, Na Liu, QiJiong Li, et al.. (2025). Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma. Frontiers in Immunology. 16. 1573098–1573098.

Kan, Anna, Minke He, Huifang Li, et al.. (2024). Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma. Frontiers in Immunology. 15. 1260191–1260191. 9 indexed citations

Lai, ZhiCheng, Anna Kan, Hui Liu, et al.. (2024). TMB Signature-Related RCAN2 Promotes Apoptosis by Upregulating EHF/DR5 Pathway in Hepatocellular Carcinoma. Frontiers in Bioscience-Landmark. 29(7). 243–243.

Lai, ZhiCheng, et al.. (2024). Apatinib and camrelizumab plus hepatic arterial infusion with oxaliplatin and 5-fluorouracil vs. apatinib and camrelizumab as the first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A randomized multi-center clinical trial.. Journal of Clinical Oncology. 42(16_suppl). TPS4194–TPS4194. 2 indexed citations

Lai, ZhiCheng, et al.. (2024). Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).. Journal of Clinical Oncology. 42(16_suppl). 4113–4113. 1 indexed citations

Chen, Hailong, Minke He, ZhiCheng Lai, et al.. (2024). UBA2 SUMOylates NQO1 and promotes the proliferation of hepatocellular carcinoma by modulating the MAPK pathway. Cancer Science. 115(9). 2998–3012. 2 indexed citations

He, Minke, ZhiCheng Lai, QiJiong Li, et al.. (2023). Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. Current Opinion in Pharmacology. 70. 102362–102362. 8 indexed citations

Liu, Yanping, Cong Guo, Jun Zhang, et al.. (2023). Quality uniformity evaluation of Babao Dan capsule based on its 14 main chemical compounds and in vitro anti-inflammatory activity. Arabian Journal of Chemistry. 16(11). 105276–105276. 1 indexed citations

Lai, ZhiCheng, JingXian Shen, QiJiong Li, et al.. (2023). Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC). Clinical Cancer Research. 29(24). 5104–5115. 17 indexed citations

10.

Huang, Bin, Honglin An, Jiayu Shen, et al.. (2023). Babao Dan alleviates gut immune and microbiota disorders while impacting the TLR4/MyD88/NF-кB pathway to attenuate 5-Fluorouracil-induced intestinal injury. Biomedicine & Pharmacotherapy. 166. 115387–115387. 44 indexed citations

11.

Kan, Anna, Shuang Liu, Minke He, et al.. (2023). MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma. JHEP Reports. 6(1). 100939–100939. 8 indexed citations

12.

Wen, Dongsheng, et al.. (2023). DNA methylation-activated full-length EMX1 facilitates metastasis through EMX1-EGFR-ERK axis in hepatocellular carcinoma. Cell Death and Disease. 14(11). 769–769. 10 indexed citations

13.

Li, Yufei, Wei Liu, Yingchao Wang, et al.. (2022). Identification of bioactive ingredients from Babaodan using UPLC-QTOF-MS analysis combined with network pharmacology guided bioassays. Journal of Chromatography B. 1206. 123356–123356. 5 indexed citations

14.

Lai, ZhiCheng, Minke He, Yu-Jie Xu, et al.. (2022). Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. European Journal of Cancer. 174. 68–77. 119 indexed citations breakdown →

15.

Lai, ZhiCheng, Dongsheng Wen, Anna Kan, et al.. (2022). One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. BMC Medicine. 20(1). 415–415. 12 indexed citations

16.

He, Minke, Chuan Peng, Yang Zhao, et al.. (2021). Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. Cancer Immunology Immunotherapy. 70(11). 3207–3216. 25 indexed citations

17.

Zhao, Yang, Minke He, Dongsheng Wen, et al.. (2021). Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. Frontiers in Oncology. 11. 619461–619461. 14 indexed citations

18.

Xu, Yu-Jie, ZhiCheng Lai, Minke He, et al.. (2021). Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. Technology in Cancer Research & Treatment. 20. 2203805736–2203805736. 14 indexed citations

19.

Lai, ZhiCheng, Jinyu Liang, Li‐Da Chen, et al.. (2018). Do hepatocellular carcinomas located in subcapsular space or in proximity to vessels increase the rate of local tumor progression? A meta-analysis. Life Sciences. 207. 381–385. 17 indexed citations

20.

Zeng, Xianshang, Lili Zhang, Dan Zeng, et al.. (2017). The impact of high total cholesterol and high low-density lipoprotein on avascular necrosis of the femoral head in low-energy femoral neck fractures. Journal of Orthopaedic Surgery and Research. 12(1). 30–30. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact